Antidepressants

ESO Publishes Peer-Reviewed Paper On Prehospital Ketamine Use At A National Level

Friday, June 11, 2021 - 1:13pm

The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.

Key Points: 
  • The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.
  • View the full release here: https://www.businesswire.com/news/home/20210611005060/en/
    The ketamine conversation has reached a national, mainstream audience, said Dr. Brent Myers, Chief Medical Officer for ESO.
  • EMS Ketamine Administrations: Based on data from the ESO Data Collaborative, EMS administered ketamine to 11,291 patients from January 1, 2019-December 31, 2019.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

Wednesday, June 9, 2021 - 12:05pm

This result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.

Key Points: 
  • This result is highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress, being held virtually June 9 - 11, 2021 and June 16 - 18, 2021.
  • Our Phase 2a clinical trial data showed that IMC-1 treated patients had higher overall completion rates and lower rates of discontinuation due to adverse events, as compared with placebo-treated patients.
  • In this study, IMC1 demonstrated significant reductions in pain, fatigue, and other important symptoms in patients with FM.
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.

American Journal of Psychiatry Publishes International Ketamine and Esketamine Treatment Guidance Led by Braxia Scientific CEO Dr. Roger Mcintyre

Wednesday, June 9, 2021 - 12:05pm

The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.

Key Points: 
  • The Guidelines were developed and led by Braxia's CEO Dr. Roger S. McIntyre, M.D., and Braxia Health Medical Director, Joshua Rosenblat, M.D., M.
  • Both Esketamine and intravenous (IV) Ketamine are the first glutamate-based treatments demonstrated to be rapidly effective in adults suffering from TRD.
  • "We have been encouraged to see increased availability and access to esketamine and ketamine for adults experiencing TRD.
  • We have been equally interested to assure that implementation of these rapid-acting treatments is conducted according to the best of science and clinical practice parameters," said Dr. Roger S. McIntyre, CEO, Braxia Scientific.

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

Thursday, June 3, 2021 - 11:00am

Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.

Key Points: 
  • Pursuant to the terms of the Agreement and subject to the closing of the Transaction, IRPs Founder and Chief Executive Officer (CEO), Steven Inglefield, has agreed to become a director of Ketamine One.
  • The IRP team is excited to join Ketamine One and combine resources to grow its clinics across Canada.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Friday, May 21, 2021 - 6:24pm

RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.

Key Points: 
  • RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.
  • In addition to these outcomes, RBX2660 provided a relative reduction of recurrence of 29.4% compared to placebo.
  • The majority of treatment emergent adverse events (TEAEs) for RBX2660 were similar to placebo, and mild to moderate in nature.
  • difficile infection is a global public health threat that requires immediate action to halt the unrelenting cycle of recurrence.

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Thursday, May 20, 2021 - 2:28pm

as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.

Key Points: 
  • as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.
  • Professor Macaluso is also the Clinical Director of the UAB Depression and Suicide Center.
  • Matt has extensive experience in conducting clinical studies involving depression, including being a principal investigator of clinical studies involving esketamine which led to an FDA approval.
  • He is also a co-inventor for the novel use of ketamine as a potential treatment for ALS.

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Thursday, May 20, 2021 - 11:30am

b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.

Key Points: 
  • b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
  • KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
  • The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
  • More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Monday, May 17, 2021 - 12:59pm

The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.

Key Points: 
  • The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.
  • The IND paves the way for us to expeditiously evaluate ketamine and other psychedelics via the FDA regulatory pathway in various mental illness, neurological and pain disorders.
  • There is currently no cure for Parkinson\xe2\x80\x99s disease, although some drug combinations are used to treat the disease symptoms.
  • The possible therapeutic effect of low-dose ketamine on LID was noted in a retrospective analysis of PD patients who received ketamine for pain relief.

Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children

Thursday, May 13, 2021 - 12:05pm

"\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.

Key Points: 
  • "\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.
  • "Since opening our clinics less than 3 years ago, we have administered over 3,000 Intravenous Ketamine Infusionsand over 60 Intranasal Ketamine treatments.
  • Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression.
  • "\nThe clinic is to be operated as a joint venture, owned equally by the Company and NMC.

Leading CBD, gummy manufacturer Global Widget launches Defense Boost line of immune support gummies

Friday, May 7, 2021 - 3:00pm

"We\'ve expanded our in-house gummy manufacturing capacity and capabilities to introduce non-CBD products that specifically help people boost and maintain their immune systems.

Key Points: 
  • "We\'ve expanded our in-house gummy manufacturing capacity and capabilities to introduce non-CBD products that specifically help people boost and maintain their immune systems.
  • "\nFor information on Defense Boost, retailers can visit www.defenseboost.com .\nGlobal Widget, founded in 2016 and headquartered in Tampa, Florida, is a vertically integrated CPG manufacturer, distributor and marketer of CBD and health and wellness products, and a leader in gummy production and packaging.
  • The company is the trusted powerhouse behind the iconic CBD brand Hemp Bombs, along with health and wellness brands, Defense Boost, Mystic Labs and Black Diamond Kratom.
  • With more than 110,000 square feet of facility space and more than 200 employees, Global Widget is one of the nation\'s largest CBD companies and a leading contract manufacturer providing quality products and support services to retailers and distributors worldwide.